Chipscreen(SH:688321) Zheng Quan Zhi Xing·2025-09-01 16:10Group 1 - The company announced the resignation of Vice General Manager Zhang Libin due to personal reasons, effective immediately, and he will not hold any other positions within the company after his resignation [1][2]. - Zhang Libin's resignation will not adversely affect the company's daily operations, as the responsibilities will be taken over by She Liangji, the Senior Vice President of the Group, who will directly lead the department [2][3]. - The company expressed gratitude for Zhang Libin's contributions during his tenure [2]. Group 2 - The company has upgraded its organizational structure, with She Liangji overseeing the commercial sector, which includes the oncology product division, metabolic disease product division, and commercial and market access department [2]. - A new "new retail" business department has been established to enhance online brand promotion and diversify sales channels, reflecting the company's strategic response to market demands [2]. - The sales revenue from the "sugar liver co-management" initiative has increased by 125.7% year-on-year, indicating strong market recognition [2].